SCHEMBL30800484

SCHEMBL30800484

CC(F)CNc1ccc([N+](=O)[O-])cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.61
CA12 O43570 1/20 0.57
CA1 P00915 1/20 0.57
CA2 P00918 1/20 0.57
CA9 Q16790 1/20 0.57
ALDH1A1 P00352 7/20 0.52
RECQL P46063 1/20 0.52
HSD17B10 Q99714 1/20 0.52
SMN1; SMN2 Q16637 4/20 0.51
GLA P06280 2/20 0.51
MEN1 O00255 4/20 0.51
KMT2A Q03164 4/20 0.51
HPGD P15428 2/20 0.51
HTT P42858 1/20 0.51
KDM4E B2RXH2 1/20 0.48
RAB9A P51151 1/20 0.48
PTPRF P10586 1/20 0.46
PTPN2 P17706 1/20 0.46
PTPN1 P18031 1/20 0.46
PTPN11 Q06124 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8635097 0.86 MAPT (0.65) MAPTALDH1A1RECQLHSD17B10SMN1; SMN2
Ammonia Solution, Strong SCHEMBL6701329 0.84 MAPT (0.62) MAPTALDH1A1RECQLHSD17B10SMN1; SMN2
SCHEMBL9820267 0.83 MAPT (0.61) MAPTALDH1A1RECQLHSD17B10SMN1; SMN2
SCHEMBL6563884 0.83 MAPT (0.61) MAPTCA1CA2ALDH1A1RECQL
SCHEMBL4616467 0.81 MAPT (0.59) MAPTCA12CA1ALDH1A1RECQL
SCHEMBL11214950 0.80 MAPT (0.57) MAPTALDH1A1RECQLHSD17B10SMN1; SMN2
SCHEMBL4616173 0.80 ALDH1A1 (0.56) MAPTALDH1A1RECQLHSD17B10SMN1; SMN2
SCHEMBL9003269 0.79 MAPT (0.70) MAPTALDH1A1RECQLHSD17B10SMN1; SMN2
SCHEMBL5157176 0.79 MAPT (0.59) MAPTCA12CA1ALDH1A1RECQL
SCHEMBL3662904 0.79 MAPT (0.59) MAPTCA12CA1ALDH1A1RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125349-A1 PROCESS FOR THE FLUORINATION AND/OR CYCLIZATION OF AN AMINO ALKENE OR ALKYNE IN A CONTINUOUS STREAM AND FACILITY FOR PERFORMING THE PROCESS UNIV POITIERS (FR) 2026-05-07 US disclosed
EP-4598903-A1 PROCESS FOR THE FLUORINATION AND/OR CYCLIZATION OF AN AMINO ALKENE OR ALKYNE IN A CONTINUOUS STREAM AND FACILITY FOR PERFORMING THE PROCESS Université de Poitiers (FR) 2025-08-13 EP disclosed
CN-120035579-A Process for fluorinating and/or cyclizing an amino alkene or alkyne in a continuous flow and apparatus for carrying out the process 普瓦捷大学 2025-05-23 CN disclosed
WO-2024074501-A1 PROCESS FOR THE FLUORINATION AND/OR CYCLIZATION OF AN AMINO ALKENE OR ALKYNE IN A CONTINUOUS STREAM AND FACILITY FOR PERFORMING THE PROCESS UNIVERSITE DE POITIERS (FR) 2024-04-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125349-A1 PROCESS FOR THE FLUORINATION AND/OR CYCLIZATION OF AN AMINO ALKENE OR ALKYNE IN A CONTINUOUS STREAM AND FACILITY FOR PERFORMING THE PROCESS FIBP, FGB, SUB1 MAPT 4200/4885CA12 1001/4885CA1 382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.